Yubo International Biotech Limited is a biotech company focused on endometrial stem cells, healthcare products, and stem cell services, with a principal subsidiary in Beijing.

# Company Overview - Yubo International Biotech Limited

## Business Focus
- Yubo Beijing, a wholly owned subsidiary of the company, specializes in the research, development, and application of **endometrial stem cells**.
- The company is committed to creating the **world’s first public endometrial stem cell repository**.
- It offers products and services under the brand **“VIVCELL”**.

## Product Offerings
- **Healthcare Products**:
  - Respiratory system products (e.g., nebulizers with medical fluids)
  - Skincare products
  - Hair care products
  - Healthy beverages
  - Male and female personal care products
  
- **Stem Cell Related Services**:
  - Cell testing
  - Health management consulting

## Business Model
- Builds a **public endometrial stem cell resource library** to supply high-quality cells to medical and research centers.
- Operates **biological experience centers** for display, trial, and sale of light application products, training sales personnel, and expanding into franchise networks.

## Technology & Innovation
- Focuses on **stem cell storage facilities** and **light application products** targeting health, skincare, and personal care.
- Owns **one invention patent (CN106264688B)** for menstrual blood collection kit, expiring in 2039.
- Advanced in developing **medical-grade cell therapeutic products**, **anti-aging treatments**, and **clinical transformation** of stem cell technologies.

## Regulatory & Operational Details
- Operates a **stem cell bank** in Chengdu, with plans to expand capacity by 2030.
- Currently has **18 employees**.
- Has obtained key licenses including food operation and medical licenses.
- Engages third-party manufacturers for light application products and medical devices.

## Revenue & Financials
- **2024 Revenue:** $3,470
- **2023 Revenue:** $604,676
- **2024 Gross Profit:** $2,648
- **2023 Gross Profit:** $419,185
- **2024 Operating Expenses:** $1,772,567
- **2023 Operating Expenses:** $1,613,891
- **2024 Net Loss:** $1,981,792
- **2023 Net Loss:** $1,195,083

## Market & Customers
- Relies heavily on a **small number of customers**, with **one customer** accounting for **100% of revenue in 2024** and **37% in 2022**.
- Total stockholders: approximately **456 Class A** and **38 Class B**.
- No current **public trading market** for Class B shares; Class A shares are quoted on OTC Marketplace with recent price of **$0.0494** per share.
- No dividends paid; company plans to retain earnings for growth.

## Employees
- **18 employees** at Yubo Beijing, including:
  - 3 executives
  - 2 finance personnel
  - 2 admin staff
  - 2 commercial staff
  - 1 business development
  - 7 marketing/planning
  - 1 IT management

## Other Notes
- The company is structured as a U.S. holding company with a **Variable Interest Entity (VIE)** in China, specifically Yubo Beijing.
- Contractual arrangements with Yubo Beijing have not been tested in court.
- The company operates mainly through contractual control rather than direct ownership in China.

Yubo International Biotech Limited focuses on advanced biotechnology, particularly in endometrial stem cell research and healthcare products, aiming to establish a global repository for stem cells.

## Company Overview: Yubo International Biotech Limited

### General Information
- **Name:** Yubo International Biotech Limited 
- **Former Name:** Magna-Lab, Inc.
- **Incorporation:** New York, U.S.
- **Subsidiaries:** Includes Platinum International Biotech Co., Ltd., Platinum International Biotech (Hong Kong) Limited, and Yubo International Biotech (Chengdu) Limited. 

### Business Structure
- **Holding Company:** Yubo International Biotech Limited is a U.S. holding company operating primarily through its wholly-owned subsidiary, Platinum, which serves as a Cayman Islands holding company.  
- **Variable Interest Entity (VIE):** Yubo Beijing, a variable interest entity in China, is controlled through contractual agreements rather than direct equity ownership.
  
### Operations and Services
- **Core Focus:** Yubo Beijing conducts day-to-day operations in China centering on the research and development and application of endometrial stem cells, particularly aiming to build the first public endometrial stem cell repository globally.
- **Product Offerings:** 
  - **Healthcare Products:** Respiratory healthcare products, skincare, hair care, healthy beverages, and personal care products for both males and females.
  - **Stem Cell Services:** Includes cell testing and health management consulting.
  - **Branding:** Operations are branded under "VIVCELL."

### Customers
- **Target Market:** The customer base mainly includes middle and high-income individuals suffering from various health conditions.
- **Key Products and Target Customers:**
  - **Respiratory Atomization Products:** Targeted towards individuals with respiratory diseases, marketed in multiple provinces such as Guangdong and Sichuan.
  - **Cell Basidiomycetes Compound Drink:** Targeting patients recovering from severe conditions or with lower immunity.
  - **Facial Care, Eye Care, and Hair Care Series:** Targeting high-income populations with specific needs (e.g., dry skin, hair thinning).

### Workforce
- **Employees:** Yubo Beijing employs 18 individuals as of the date of the report, distributed across various functions including management, finance, administration, and marketing.

### Financial Information
- **Revenue:** Specific revenue figures are not provided in the text, but operating results indicate that Yubo Beijing has not generated any after-tax profit to date.
- **Profitability:** Yubo has a history of losses, raising doubt about its ability to continue as a going concern. The operational model indicates a reliance on future growth in the highly competitive biotech industry.

### Recent Developments
- **Acquisitions:** On October 10, 2023, Yubo Beijing acquired a wholly-owned subsidiary, Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd., aiming to expand technical services and technical promotions including medical device sales.

### Business Strategy
- **Stem Cell Storage Facility:** Plans to develop a first-class stem cell storage facility catering to healthcare demands.
- **Future Growth:** Intends to expand its product line into medical-grade cell therapeutic products and establish biological experience center stores as franchise operations under the “VIVCELL” brand.

### Risks and Challenges
- **Regulatory Environment:** Face risks related to strict Chinese regulations forced by local laws regarding foreign ownership and control.
- **Intellectual Property:** Yubo Beijing has one registered patent and relies heavily on trade secrets and proprietary technology.
- **Market Competition:** Competes with a multitude of firms within the extensive biomedical and healthcare industries with uncertainties related to market acceptance. 

### Summary
Yubo International Biotech Limited aims to leverage advanced biotechnology focused on stem cell research and applications while navigating regulatory complexities and a competitive market landscape.

Yubo International Biotech Ltd

10-K / March 31, 2025

10-K / April 12, 2024

10-K / March 31, 2025

Company Overview - Yubo International Biotech Limited

Business Focus

Product Offerings

Business Model

Technology & Innovation

Regulatory & Operational Details

Revenue & Financials

Market & Customers

Employees

Other Notes